16 completed, 1 not yet recruiting, 1 terminated, 1 withdrawn. 19 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 16, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Fungal Infection: new trials by email Literature Review of Fungal Infection trials Research Report on Fungal Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD5CAR-NK Cells for Refractory Invasive Mold Disease CD5CAR-CBNK - Fungal Infection | Phase 1 | Not yet recruiting | Fundacion Clinic per a la Recerca Biomédica | 10 | 2026-05-01 | 2026-03-06 |
| Effect of Administration of Combined Enteral Lactoferrin and Probiotic On Invasive Fungal Infections In Preterm Neonates Lactoferrin Bovine, Lactoferrin Bovine and probiotics, Placebo - Fungal Infection | Phase 1 | Completed | Ain Shams University | 80 | 2020-02-10 | 2022-03-16 |
| ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects [14C]-Ibrexafungerp - Fungal Infection | Phase 1 | Completed | Scynexis, Inc. | 6 | 2019-12-05 | 2020-08-14 |
| Safety and Pharmacokinetics of Rezafungin Placebo, Rezafungin - Fungal Infection | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 14 | 2019-12-04 | 2021-07-16 |
| A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 APX001, Itraconazole, Rifampin - Fungal Infection | Phase 1 | Completed | Basilea Pharmaceutica | 36 | 2019-11-12 | 2024-05-17 |
| A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen Voriconazole Oral Product (Vfend®) - Fungal Infection | Phase 1 | Completed | Seoul National University Hospital | 11 | 2018-08-20 | 2018-11-30 |
| A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males [14C]-APX001 Oral Solution, [14C]-APX001 Solution for Infusion - Fungal Infection | Phase 1 | Completed | Basilea Pharmaceutica | 10 | 2018-08-17 | 2024-05-17 |
| Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) Posaconazole - Fungal Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 70 | 2017-12-20 | 2019-12-19 |
| Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally APX001 single IV dose, APX001 single oral dose 1, APX001 single oral dose 2 - Fungal Infection | Phase 1 | Completed | Basilea Pharmaceutica | 46 | 2016-10-31 | 2025-09-10 |
| Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects APX001 single dose 1, APX001 single dose 2, APX001 single dose 3 - Fungal Infection | Phase 1 | Completed | Basilea Pharmaceutica | 200 | 2016-05-24 | 2025-09-10 |
| Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) Posaconazole - Fungal Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 65 | 2015-05-06 | 2018-10-09 |
| MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients Voriconazole - Fungal Infection | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 66 | 2015-01-19 | 2019-04-29 |
| Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO) Fluconazole - Cardiopulmonary Arrest, Fungal Infection | Phase 1 | Completed | Michael Cohen-Wolkowiez | 21 | 2010-07-01 | 2017-11-22 |
| Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520) Posaconazole, Dextrose 5% in water - Fungal Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 279 | 2010-02-23 | 2017-11-13 |
| Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir Posaconazole, Fosamprenavir, Ritonavir - HIV Infection, Fungal Infection | Phase 1 | Completed | Radboud University Medical Center | 24 | 2009-01-01 | 2020-11-12 |
| Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients human lactoferrin (hLF1-11) - Fungal Infection, Bacterial Infection | Phase 1 / Phase 2 | Withdrawn | AM-Pharma | 2008-11-01 | 2015-06-30 | |
| TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. TMC125 - HIV, AIDS | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 18 | 2008-09-01 | 2011-06-09 |
| Alternate Day Micafungin: A PK Study in Pediatric Patients Micafungin - Fungal Infection | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 15 | 2007-07-01 | 2012-02-16 |
| Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy Voriconazole - Fungal Infection | Phase 1 | Completed | Pfizer | 12 | 2005-04-01 | 2009-03-12 |
Mycoses (19) · Acquired Immunodeficiency Syndrome (1) · Bacterial Infections (1) · HIV Infections (1) · Heart Arrest (1) · Infections (1) · Neutropenia (1) · Premature Birth (1)
Bacterial Infections and Mycoses (19) · Infections (18) · Urogenital Diseases (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Lentivirus Infections (2) · RNA Virus Infections (2) · Retroviridae Infections (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2) · Virus Diseases (2) · Agranulocytosis (1)
posaconazole (4) · Voriconazole (3) · Fluconazole (1) · Glucose (1) · Itraconazole (1) · Micafungin (1) · Probiotics (1) · Rezafungin (1) · Rifampin (1) · Ritonavir (1) · Water (1) · etravirine (1) · fosamprenavir (1)
Basilea Pharmaceutica (4) · Merck Sharp & Dohme LLC (3) · AM-Pharma (1) · Ain Shams University (1) · Children's Hospital Medical Center, Cincinnati (1) · Fundacion Clinic per a la Recerca Biomédica (1) · Masonic Cancer Center, University of Minnesota (1) · Michael Cohen-Wolkowiez (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pfizer (1) · Radboud University Medical Center (1) · Scynexis, Inc. (1) · Seoul National University Hospital (1) · Tibotec Pharmaceuticals, Ireland (1)
Netherlands (5) · United States (4) · United Kingdom (2) · China (1) · Egypt (1) · South Korea (1) · Spain (1)
Marc Engelhardt (4) · Angela Smith, M.D. (1) · David M Burger, PharmD PhD (1) · Hebatallah A Shaaban, MD (1) · Kevin M Watt, MD (1) · Nkechi Azie, MD (1) · Parinda Mehta, MD (1) · Peter J Donnelly, PhD (1) · Pui-Yang Iroh Tam, M.D. (1)
PMID 36988461, PMID 20667889, PMID 23400742, PMID 24733463, PMID 28961714, PMID 32319040, PMID 34970774, PMID 35167031, PMID 38757982, PMID 39012090
2025 (1)